Building Better Biotech Financial Models and Managing Valuation Risk with Frank David

Financial Modeler's Corner

In this episode of Financial Modeler’s Corner, host Paul Barnhurst (aka the FP&A Guy) sits down with Frank David, an expert at the intersection of corporate strategy, clinical medicine, and biotech research. They discuss the unique challenges of financial modeling in the biopharma industry, the importance of understanding patient populations, and how drug development strategy influences financial decision-making.

Frank David is the Founder and Managing Director of Pharmagellan, a consulting firm specializing in biotech financial modeling and valuation. With a background as a physician scientist, Frank has extensive experience advising biopharma teams and investors. He also teaches at Tufts University and is the lead author of The Pharmagellan Guide to Biotech Forecasting and Valuation and The Pharmagellan Guide to Analyzing Biotech Clinical Trials.

Expect to Learn:

• The unique challenges of financial modeling in biotech and pharma.
• Why "small percent of a big market" is a flawed valuation approach.
• How patient segmentation impacts drug development strategy.
• The importance of risk-adjusted modeling and scenario planning.
• How financial modeling supports strategic decision-making in biotech investments.

Here are a few quotes from the episode:

• "Most early-stage biotech entrepreneurs don’t realize they need to think about who their patients actually are and what alternative treatments exist."
• "In drug development, forecasting is about managing uncertainty, not predicting exact numbers."
• "The clinical strategy and commercial strategy in biotech are so intertwined that modeling them separately can be misleading."

This episode explored the complexities of biotech financial modeling. Frank shared why traditional financial modeling approaches don’t always work in the biotech industry and how strategic decision-making relies heavily on understanding patient needs, regulatory pathways, and risk assessment.

Follow Frank:

• LinkedIn - https://www.linkedin.com/in/frank-s-david/
• Company - https://www.pharmagellan.com/
• Email - [email protected]
• Book - https://a.co/d/gf8SwzI

Follow Paul:

• Website - https://www.thefpandaguy.com  
• LinkedIn - https://www.linkedin.com/in/thefpandaguy 
• YouTube - https://www.youtube.com/@thefpaguy8376 

Follow Financial Modeler's Corner 

• LinkedIn Page- https://www.linkedin.com/company/financial-modeler-s-corner/?viewAsMember=true 
• Newsletter - Subscribe on LinkedIn-https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=7079020077076905984

Sign up for the Advanced Financial Modeler Accreditation Today and receive 15% off by using the special show code ‘Podcast’.

Visit https://bit.ly/497oAqW and use the code “Podcast” to save 15% when you register. 

In today’s episode:

[01:14] - Introduction to the Episode

[02:02] - Meet Frank David

[04:17] - Financial Modeling Horror Story

[09:38] - Understanding Biotech Financial Models

[13:57] - Biotech Forecasting and Valuation

[18:15] - Where to Start When Analyzing a Drug Project

[24:52] - Risk-Adjusted Modeling in Biotech

[32:01] - Advice for Modelers in Biotech

[40:56] - Fun & Rapid-Fire Questions

[49:32] - How to Connect with Frank David